Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis

Affiliations

• ¹ Department of Medical Sciences and Public Health, University of Cagliari, Cagliari.
• ² Businco Hospital, Hematology and Transplant Center, Cagliari.
• ³ Hematology Unit, Cardarelli Hospital, Naples.
• ⁴ Hematology Unit "Federico II" University of Naples, Naples.
• ⁵ Department of Medicine, Section of Hematology, University of Verona, Verona.
• ⁶ Hematology Unit, "Fondazione IRCCS Policlinico S. Matteo" University Hospital, Pavia.
• ⁷ Hematology Unit, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino.
• ⁸ Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa.
• ⁹ Hematology and Transplants Unit, University of Bari, Bari.
• ¹⁰ Hematology Unit, Sant'Eugenio Hospital Tor Vergata University, Rome.
• ¹¹ Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano.
• ¹² Hematology Unit, Azienda Ospedaliera "Bianchi-Melacrino-Morelli", Reggio Calabria.
• ¹³ Casa Sollievo della Sofferenza Hospital, Hematology and Transplant Center, San Giovanni Rotondo.
• ¹⁴ Hematology Unit, University of Padova, Padua.
• ¹⁵ Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna.
• ¹⁶ Hematology Unit, AOU Careggi, University of Florence, Florence.
• ¹⁷ Department of Clinical and Experimental Medicine, University of Sassari, Sassari.
• ¹⁸ Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena.
• ¹⁹ Hematology Unit, Ferrarotto Hospital, Catania.
• ²⁰ Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome.
• ²¹ Division of Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy.